Literature DB >> 18814145

Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Philomena Arrenberg1, Ramesh Halder, Vipin Kumar.   

Abstract

Natural killer T (NKT) cells generally recognize lipid-antigens presented in the context of the MHC class I-like molecule CD1d. CD1d-restricted NKT cells consist of two broad subsets: Type I, which express an invariant T cell receptor (TCR) and type II, which utilize diverse TCR gene segments. A major type II NKT subset has been shown to recognize a self-glycolipid, sulfatide. Both subsets play important roles in autoimmune diseases, tumor surveillance, and infectious diseases. While type I NKT cells protect from tumor growth by enhancing tumor surveillance, type II NKT cells may suppress anti-tumor immune responses. In a murine autoimmune hepatitis model, type I NKT cells contribute to pathogenesis, whereas activation of sulfatide-reactive type II NKT cells protects from disease. Sulfatide-mediated activation of type II NKT cells results in modification of dendritic cells and induction of anergy in type I NKT cells. Elucidation of this novel pathway of cross-regulation among NKT cell subsets will provide tools for intervention in autoimmune diseases and for designing strategies for effective anti-tumor immunity. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18814145      PMCID: PMC2653050          DOI: 10.1002/jcp.21597

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  81 in total

Review 1.  NKT cells - conductors of tumor immunity?

Authors:  Mark J Smyth; Nadine Y Crowe; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita; Dale I Godfrey
Journal:  Curr Opin Immunol       Date:  2002-04       Impact factor: 7.486

Review 2.  The unconventional lifestyle of NKT cells.

Authors:  Mitchell Kronenberg; Laurent Gapin
Journal:  Nat Rev Immunol       Date:  2002-08       Impact factor: 53.106

3.  Population pharmacokinetics of the novel anticancer agent KRN7000.

Authors:  Mirjam Crul; Ron A Mathôt; Giuseppe Giaccone; Cornelis A Punt; Hilde Rosing; Michel X Hillebrand; Yoshitaka Ando; Nobosuke Nishi; Hideji Tanaka; Jan M Schellens; Jos H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  2002-01-24       Impact factor: 3.333

4.  Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules?

Authors:  Tim Fiedler; Wolfgang Walter; Torsten E Reichert; Markus J Maeurer
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

5.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.

Authors:  K Miyamoto; S Miyake; T Yamamura
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice.

Authors:  Lucia Sfondrini; Dario Besusso; Maria Teresa Zoia; Monica Rodolfo; Anna Maria Invernizzi; Masaru Taniguchi; Toshinori Nakayama; Mario Paolo Colombo; Sylvie Ménard; Andrea Balsari
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

7.  Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.

Authors:  A K Singh; M T Wilson; S Hong; D Olivares-Villagómez; C Du; A K Stanic; S Joyce; S Sriram; Y Koezuka; L Van Kaer
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

8.  Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis.

Authors:  A W Jahng; I Maricic; B Pedersen; N Burdin; O Naidenko; M Kronenberg; Y Koezuka; V Kumar
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

9.  Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining.

Authors:  Jenny E Gumperz; Sachiko Miyake; Takashi Yamamura; Michael B Brenner
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

10.  A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.

Authors:  Nadine Y Crowe; Mark J Smyth; Dale I Godfrey
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

View more
  41 in total

1.  Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis.

Authors:  Laurent Mesnard; Alexandre C Keller; Marie-Laure Michel; Sophie Vandermeersch; Cédric Rafat; Emmanuel Letavernier; Yves Tillet; Eric Rondeau; Maria C Leite-de-Moraes
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

2.  NKT cells turn ten.

Authors:  Peter D Burrows; Mitchell Kronenberg; Masaru Taniguchi
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

3.  Altered peripheral invariant natural killer T cells in atopic dermatitis.

Authors:  Edit Gyimesi; Georgina Nagy; Éva Remenyik; Sándor Sipka; Margit Zeher; Tamás Bíró; Andrea Szegedi
Journal:  J Clin Immunol       Date:  2011-06-21       Impact factor: 8.317

4.  Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease.

Authors:  Igor Maricic; Enrico Girardi; Dirk M Zajonc; Vipin Kumar
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

5.  Beta-glucosylceramide administration (i.p.) activates natural killer T cells in vivo and prevents tumor metastasis in mice.

Authors:  Masashi Inafuku; Changchun Li; Yasuhiro Kanda; Toshihiko Kawamura; Kazuyoshi Takeda; Hirosuke Oku; Hisami Watanabe
Journal:  Lipids       Date:  2012-03-20       Impact factor: 1.880

Review 6.  Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Luc Van Kaer; Lan Wu; Vrajesh V Parekh
Journal:  Immunology       Date:  2015-06-22       Impact factor: 7.397

Review 7.  Different subsets of natural killer T cells may vary in their roles in health and disease.

Authors:  Vipin Kumar; Terry L Delovitch
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

8.  Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury.

Authors:  Seung Hee Yang; Jung Pyo Lee; Hye Ryoun Jang; Ran-hui Cha; Seung Seok Han; Un Sil Jeon; Dong Ki Kim; Junghan Song; Dong-Sup Lee; Yon Su Kim
Journal:  J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 10.121

9.  B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.

Authors:  Carolin Brandl; Sonja Ortler; Thomas Herrmann; Susanna Cardell; Manfred B Lutz; Heinz Wiendl
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

Review 10.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.